Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia

Author:

Walter Roland B.12ORCID,Michaelis Laura C.3,Othus Megan4,Uy Geoffrey L.5,Radich Jerald P.12,Little Richard F.6ORCID,Hita Sandi7,Saini Lalit8,Foran James M.9,Gerds Aaron T.10ORCID,Klepin Heidi D.11,Hay Annette E.12,Assouline Sarit13,Lancet Jeffrey E.14ORCID,Couban Stephen15,Litzow Mark R.16,Stone Richard M.17,Erba Harry P.18

Affiliation:

1. Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle Washington

2. Department of Medicine; University of Washington; Seattle Washington

3. Department of Hematology and Oncology; Medical College of Wisconsin; Milwaukee Wisconsin

4. SWOG Statistical Center, Fred Hutchinson Cancer Research Center; Seattle Washington

5. Division of Oncology, Department of Medicine; Washington University School of Medicine; St Louis Missouri

6. Cancer Therapy Evaluation Program, National Cancer Institute; Rockville Madison

7. SWOG Operations; San Antonio Texas

8. Department of Medicine; University of Alberta; Edmonton Alberta Canada

9. Division of Hematology and Oncology; Mayo Clinic; Jacksonville Florida

10. Department of Hematology and Medical Oncology; Cleveland Clinic Taussig Cancer Institute; Cleveland Ohio

11. Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University; Winston-Salem North Carolina

12. Department of Medicine; Queen's University; Kingston Ontario Canada

13. Jewish General Hospital; Montreal Quebec Canada

14. Moffitt Cancer Center; Tampa Florida

15. Division of Hematology; Dalhousie University; Halifax Nova Scotia Canada

16. Division of Hematology, Department of Internal Medicine; Mayo Clinic; Rochester Minnesota

17. Adult Leukemia Program, Dana-Farber Cancer Institute, Harvard Medical School; Boston Massachusetts

18. Division of Hematology/Oncology; University of Alabama at Birmingham; Birmingham Alabama

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3